alzheimer's

Cassava Sciences Inc. (NASDAQ:SAVA) on Tuesday shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease. REFOCUS-ALZ randomized approximately 1,125 people utilizing the same eligibility criteria as RETHINK-ALZ. Topline data indicate that...

On Tuesday, HC Wainwright initiated coverage on Alpha Cognition Inc (NASDAQ:ACOG), noting a new twist on a tried-and-tested treatment paradigm. Alpha Cognition’s lead product, Zunveyl (benzgalantamine), is a prodrug of galantamine—a well-known, long-marketed acetyl cholinesterase inhibitor...

IGC Pharma, Inc.(NYSE:IGC) reported additional interim data from its ongoing Phase 2 clinical trial evaluating IGC-AD1 for agitation in dementia associated with Alzheimer's disease. IGC-AD1 targets neuro-inflammation and CB1 receptor dysfunction,. The investigational drug contains THC as one of two...

On Tuesday, Eli Lilly And Co (NYSE:LLY) released results from the TRAILBLAZER-ALZ 6 Phase 3b study to investigate different dosing regimens of donanemab and their effect on amyloid-related imaging abnormalities with edema/effusion (ARIA-E) in adults with early symptomatic Alzheimer’...

AbbVie Inc (NYSE:ABBV) will be reporting its third-quarter earnings on Wednesday. Wall Street expects $2.92 in EPS and $14.28 billion in revenues as the company reports before market hours. Ahead of its third-quarter earnings report, AbbVie bolstered its Alzheimer's research efforts with the $1.4...

Editor’s Note: The title of the story has been updated. The original title incorrectly stated that the device is implantable On Monday, Nexalin Technology, Inc. (NASDAQ:NXL) announced the publication of a study in the Journal of Alzheimer’s Disease. The study builds on recent findings...

On Thursday, Nexalin Technology, Inc (NASDAQ:NXL) (NASDAQ:NXLIW) announced results from a clinical trial of its Deep Intracranial Frequency Stimulation (DIFS) technology for mild Alzheimer’s disease. The full results have been published in Alzheimer’s Research & Therapy. The study...

Tuesday, Sage Therapeutics, Inc. (NASDAQ:SAGE) released topline results from the Phase 2 LIGHTWAVE study to evaluate the effects of dalzanemdor (SAGE-718) in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s Disease (AD). The LIGHTWAVE Study did not...

On Wednesday, Athira Pharma, Inc. (NASDAQ:ATHA) stock is trading lower after the company released topline results from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer’s disease (AD). A -0.08 change in GST (the Global Statistical Test, a combination of...

Cassava Sciences (NASDAQ:SAVA) has engaged the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) amid ongoing investigations into the company and two senior employees. Cassava’s board formed an Ad Hoc Investigation Committee to oversee outside counsel...

The credibility of the clinical trial results for an experimental Alzheimer’s drug has been called into question following a critical inspection report by the Food and Drug Administration (FDA). What Happened: The FDA report, which was released under the Freedom of Information Act,...

Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this memory-robbing disease.  Clinical trials for at least seven Alzheimer's disease...

The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval. Alzheimer’s disease is a brain disease that leads to cognitive decline, impacting more than six...

Major Wall Street indices closed mixed on Tuesday as a disparate set of corporate earnings dampened the existing euphoria over the possibility of a slowdown in rate hikes. Although the Dow Jones closed 0.31% higher, the Nasdaq Composite ended the session 0.27% lower and the S&P 500, too,...

Silo Pharma Inc. (NASDAQ: SILO) has agreed with Columbia University to an extension of the psychedelics biotech company's option to license certain treatments currently under development, including Alzheimer’s disease and stress-induced anxiety. The compounds being...